MTFB News

Sandwiched between the election and Thanksgiving, the US IPO market had another slow week for new offerings. Meanwhile, recent news and a string of initial filings signals that companies are preparing for IPOs in December and early 2017. Those plans are supported by the S&P 500's two-week rally of +4.7%; during the same time, year-to-date performance for 2016 IPOs has...read more

Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, raised $17 million by offering 2.4 million ADSs at $6.98, or $25 million including a European placement. Motif, which is listed on London's AIM market (MTFB), originally filed in July to raise $35 million, when its converted shares traded at $12.42. Its shares on the AIM closed Thursday...read more

Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, lowered the proposed deal size for its upcoming IPO on Monday. The New York, NY-based company now plans to raise $24 million by offering 2.9 million shares at a price of $8.38. The company had previously filed to offer 2.1 million shares at $12.36. At the revised price, Motif Bio will...read more

Apart from the three companies that were on the IPO calendar last week, the only new addition is micro-cap biotech Accelerated Pharma. ...read more